Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine

NCT00080262 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT00080262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00080262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine
Lead sponsor
R-Pharm
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2004
Completion date
December 31, 2006
Enrollment
125
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastases